Prevymis (letermovir) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   32 Trials   32 Trials   1662 News 


«12345678910111213...2425»
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Journal:  Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Pubmed Central) -  Jul 15, 2024   
    As in previous CMV antiviral trials, the detection of nonviable mutations, even in multiple study subjects, raises strong suspicion of genotyping artifacts and encourages the use of replicate testing for authentication of atypical mutation readouts. The non-viability of UL89 D344Y also confirms the biologically important locus of the D344E substitution that confers resistance to benzimidazole CMV terminase complex inhibitors, but does not feature prominently in LMV resistance.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Review, Journal:  Viral Genomic DNA Packaging Machinery. (Pubmed Central) -  Jul 4, 2024   
    DNA packaging motor proteins represent excellent targets for antiviral therapy, with Letermovir, which binds Cytomegalovirus terminase, already licensed as an effective prophylaxis...Multiple high-resolution structures of each component have been resolved for different phages, but it is only more recently that the field has moved towards cryo-EM reconstructions of protein complexes. In conjunction with highly informative single-particle studies of packaging kinetics, these structures have begun to inspire models for the packaging process and its place among other DNA machines.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Journal, Pre-transplantation, Post-transplantation:  CMV Reactivation during Pre-Transplantation Evaluation: A Novel Risk Factor for Post-Transplantation CMV Reactivation. (Pubmed Central) -  Jun 26, 2024   
    Pre-HCT CMV reactivation was assessed in HCT candidates from the preemptive antiviral therapy (2007-17) and letermovir prophylaxis (2018-21) eras...Pre-HCT CMV reactivation can be routinely detected in high-risk HCT candidates and is a significant risk factor for post-HCT CMV reactivation and disease. Pre-HCT CMV DNA PCR surveillance is recommended in high-risk HCT candidates and antiviral therapy may be indicated to prevent post-HCT CMV reactivation.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Journal:  Immune milestones to predict CMV after letermovir. (Pubmed Central) -  Jun 11, 2024   
    Blips can occur during prophylaxis and do not require LET discontinuation. No abstract available
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche, Livtencity (maribavir) / Takeda, GSK
    Preclinical, Journal:  A broadly neutralizing human monoclonal antibody generated from transgenic mice immunized with HCMV particles limits virus infection and proliferation. (Pubmed Central) -  Jun 4, 2024   
    Here, we describe one such mAb, which was found to target gH/gL envelope complexes and effectively limit HCMV infection and dissemination. Further, administration of the antibody in combination with the antiviral drug ganciclovir inhibited HCMV in a synergistic manner, highlighting this approach and the use of anti-HCMV mAbs more broadly, as a potential therapeutic strategy for the treatment of diverse patient populations.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Enrollment open:  A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients (clinicaltrials.gov) -  Jun 2, 2024   
    P3,  N=143, Recruiting, 
    Further, administration of the antibody in combination with the antiviral drug ganciclovir inhibited HCMV in a synergistic manner, highlighting this approach and the use of anti-HCMV mAbs more broadly, as a potential therapeutic strategy for the treatment of diverse patient populations. Not yet recruiting --> Recruiting
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Campath (alemtuzumab) / Sanofi
    Enrollment closed, Enrollment change, Trial primary completion date:  Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab (clinicaltrials.gov) -  May 20, 2024   
    P2,  N=6, Active, not recruiting, 
    CMV primary prophylaxis with LTV abrogated the mortality gap based on CMV serostatus, a protective effect that persisted after discontinuation of primary prophylaxis. Recruiting --> Active, not recruiting | N=25 --> 6 | Trial primary completion date: Dec 2024 --> Apr 2024
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
    Case Series: CMV Viremia Associated with Sub-Acute Molecular Injury in Lung Allografts (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_2357;    
    Here, dd-cfDNA% trends correlated with CMV viremia in the absence of histologic evidence of CMV or injury. These cases suggest that (1) sub-acute molecular injury may be associated with CMV viremia after LT; (2) dd-cfDNA% may be more useful in assessing allograft injury than either spirometry or histopathology, which can affect CMV treatment algorithms.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Hot Topic Debate - CMV Prevention Strategies in High-Risk SOT: Universal Prophylaxis vs Pre-Emptive Approaches (113-ABC, Level 1) -  May 6, 2024 - Abstract #ATC2024ATC_1055;    
    Discuss impact of PET on CMV specific immunity and protection from late CMV disease Describe mechanisms to overcome the logistical barriers to implementing PET in real-world settings Review the advantages and limitations of "PET after prophylaxis" Speaker: Ajit Limaye (Alternate: Raymund Razonable) 3. Con: Universal Prophylaxis is advantageous over PET for CMV D+R- SOT recipients Explore impact of CMV DNAemia on long-term allograft outcomes ("indirect effects of CMV) Discuss the role of letermovir for CMV disease prevention in SOT recipients Describe novel interventions for CMV disease prevention in high-risk SOT recipients, including vaccinations, monoclonal antibodies, virus-specific T cells, and seromatching Speaker: Joanna Schaenman (Alternate: Camille Kotton)
  • ||||||||||  Prevymis (letermovir) / Merck (MSD), Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
    Letermovir Outperforms Valganciclovir in Mitigating Leukopenia Risks: A Comparative Analysis in Post-Lung Transplant Patients (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_992;    
    The incidence of CMV breakthrough was similar in patients receiving valganciclovir or letermovir, and patients receiving letermovir did not experience neutropenia. Letermovir appears a practical alternative for CMV prophylaxis after lung transplantation and may obviate need for management of neutropenia with costly granulocyte colony stimulating factors
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Journal:  Nipping cytomegalovirus in the bud for umbilical cord blood transplantation. (Pubmed Central) -  Apr 23, 2024   
    Real data confirm an excellent toxicity profile and effectiveness of letermovir prophylaxis with decreased cytomegalovirus reactivation and resistance in umbilical cord blood transplantation for both paediatric and adult patients...Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19451.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Journal:  Letermovir prophylaxis reduced cytomegalovirus reactivation and resistance post umbilical cord blood transplantation. (Pubmed Central) -  Apr 6, 2024   
    However, more frequent late CMV infection (31.0% vs. 4.3%, p?=?0.002) and the 180-day cumulative incidence of Epstein-Barr virus (EBV) reactivation (9.3% vs. 3.4%, p?=?0.087) were observed in UCBT patients with LET prophylaxis. Meanwhile, older age (>15?years old) and the occurrence of pre-engraftment syndrome were identified as the significant risk factors for CMV reactivation, and in patients at high risk, the incidence of CMV reactivation in the LET group was lower than that in the control group (46.7% vs. 86.5%, p?<?0.001), while this decline was less pronounced among patients at low risk (47.8% vs. 62.1%, p?=?0.120).
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Journal:  CMV-RNAemia as new marker of active viral replication in transplant recipients. (Pubmed Central) -  Mar 27, 2024   
    Meanwhile, older age (>15?years old) and the occurrence of pre-engraftment syndrome were identified as the significant risk factors for CMV reactivation, and in patients at high risk, the incidence of CMV reactivation in the LET group was lower than that in the control group (46.7% vs. 86.5%, p?<?0.001), while this decline was less pronounced among patients at low risk (47.8% vs. 62.1%, p?=?0.120). No abstract available
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Journal:  Mutagenesis and functional analysis of the varicella-zoster virus portal protein. (Pubmed Central) -  Mar 22, 2024   
    The approval of Letermovir provided proof of concept regarding the use of encapsidation inhibitors to treat herpesvirus infections in the clinic...The oligomeric portals of herpesviruses are structurally conserved, and therefore, it may be possible to find a single compound capable of targeting portals from one or more of the herpesvirus subfamilies. Drug candidates from such a series would be effective against viruses resistant to the currently available antivirals.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Enrollment closed:  Letermovir Use in Heart Transplant Recipients (clinicaltrials.gov) -  Mar 18, 2024   
    P4,  N=31, Active, not recruiting, 
    Drug candidates from such a series would be effective against viruses resistant to the currently available antivirals. Recruiting --> Active, not recruiting
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Suppressing Asymptomatic CMV With Letermovir Reshapes Cardiometabolic Proteome in Treated HIV (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_1112;    
    Suppression of asymptomatic CMV in PWH on ART increased plasma sTNFR2, but decreased markers of IL-10 receptor signaling and several inflammation and cardiometabolic proteins, some of which are causally linked to cardiovascular risk. While the clinical significance remains unclear, this is the first study to show that a specific inhibitor of CMV